Switzerland announced Tuesday it had secured an additional three million doses of the Moderna vaccine as it tries to hedge its bets between rival COVID-19 jabs.
“Since the development and availability of COVID-19 vaccines is subject to a great deal of uncertainty, the government is pursuing various options,” the Federal Office of Public Health said in a statement.
Switzerland has now secured, in total, around 7.5 million doses of US biotechnology firm Moderna’s vaccine.
It has also signed contracts for around 5.3 million doses of the AstraZeneca vaccine and, in a deal announced Monday, around three million doses of the Pfizer-BioNTech vaccine.
The wealthy Alpine nation, population 8.6 million, has therefore secured around 15.8 million vaccine doses.
With all three manufacturers’ vaccines, two doses are required per person.
The three different vaccines are currently awaiting approval from the Swissmedic national regulator.
“The federal government is still in discussion with various vaccine manufacturers,” the statement said.
“Since it is not yet clear which vaccines will prevail, it is targeting a number of… vaccines based on different technologies.”
Like the vaccine produced by Pfizer and BioNTech, US firm Moderna’s vaccine is based on a new technology that uses genetic material in the form of mRNA (messenger ribonucleic acid).
On Tuesday, Britain became the first Western country to start a mass coronavirus vaccine campaign with a 90-year-old pensioner receiving her initial dose of the Pfizer-BioNTech jab.
Switzerland will not be among the first countries to do likewise, as it does not have a process for emergency authorisations of vaccines or drugs.
The authorities have said once a vaccine is approved, they hope to scale up quickly to provide free jabs for all by mid-2021.
Switzerland has recorded 357,121 positive tests and 5,099 deaths from the coronavirus.
Follow the latest news on the coronavirus (COVID-19) outbreak
© 2020 AFP
Swiss secure three million more Moderna vaccine doses (2020, December 8)
retrieved 8 December 2020
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022